Efficient and rapid liquid reduction animal model.
- Author:
Bing HAN
;
Shu-ming KOU
;
Biao CHEN
;
Yao-zong PENG
;
Yue WANG
;
Yu-long HAN
;
Xiao-li YE
;
Xue-gang LI
- Publication Type:Journal Article
- MeSH:
Animals;
Berberine;
administration & dosage;
Cholesterol;
metabolism;
Disease Models, Animal;
Drugs, Chinese Herbal;
administration & dosage;
Female;
Humans;
Hyperlipidemias;
drug therapy;
metabolism;
Hypolipidemic Agents;
administration & dosage;
Liver;
drug effects;
metabolism;
Male;
Triglycerides;
metabolism;
Zebrafish;
metabolism
- From:
China Journal of Chinese Materia Medica
2015;40(22):4446-4451
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the practicability of establishing zebrafish lipid-lowering drug screening model and the effect of berberine (BBR) on hyperlipidemic zebrafish. Three-month-old zebrafishes were fed with 4% cholesterol for 0, 2, 4, 8, 14, 20, 25, 30 days, and the level of total cholesterol in serum was measured. Zebrafish were randomly divided into four groups: the control group, the high cholesterol diet group, the 0.01% simvastatin-treated group, the 0.1% berberine-treated group and the 0.2% berberine-treated group. The levels of total cholesterol (TC), triglyceride (TC), low density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) in serum were measured; the expression of hepatic HMGCR, LDLR and CYP7A1a mRNA expressions were detected by real time PCR. Oil red O staining was performed to observe the changes in fat content in the liver. According to the result, the level of serum TC in the 4% cholesterol diet group significantly was higher than that of the normal control group in a time-dependent manner and reached a stable level at the 20th day. The BBR group showed significant decreases in the levels of TC, TG and LDL-c, HMGCR mRNA expression and fat content and increases in LDLR and CYP7A1a mRNA. The hyperlipidemia zebrafish model was successfully established by feeding with 4% cholesterol for 20 days. The findings lay a foundation for further screenings on lipid-lowering drugs.
